Clinical Trial Update: Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study [Phase 2]

View source ↗

Summary

Phase II study evaluating preoperative FOLFIRINOX for resectable pancreatic cancer was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Pancreatic Adenocarcinoma, Poorly Differentiated Malignant Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2018-07-13